The efficacy of pharmacological interventions to improve cognitive and behavior symptoms in people with dementia: A systematic review and meta-analysis

Wisdom K. Takramah¹ ² | Livingstone Asem³

¹Department of Epidemiology and Biostatistics, School of Public Health, University of Health and Allied Sciences, Ho, Ghana
²Department of Biostatistics, School of Public Health, University of Ghana, Accra, Ghana
³Department of Health Policy, Planning and Management, School of Public Health, University of Health and Allied Sciences, Ho, Ghana

Abstract

Background and Aims: Dementia is becoming a major global public health menace in the aging population affecting 47 million people globally. Dementia has no cure and effective interventions. Treatment of dementia is a big problem. The most common symptomatic medications for cognition, behavior, and global functioning among patients with dementia currently are cholinesterase inhibitors and memantine. However, information on the effectiveness of cholinesterase inhibitors for dementia is conflicting and controversial. Thus, this makes it difficult for decision-makers, healthcare providers, patients, and caregivers to decide on the most effective intervention. The current meta-analysis sought to investigate the efficacy of pharmacologic interventions to improve cognitive and behavioral symptoms in people with living dementia.

Methods: This current systematic review and meta-analysis used the preferred reporting items for systematic reviews and meta-analyses to ensure accuracy and comprehensiveness. The Cochrane MEDLINE, Database of Systematic Reviews, and other databases were thoroughly searched for relevant studies. We selected Studies such as randomized controlled trials published in English with a sample size of at least 20 subjects. We selected and applied the random-effects meta-analysis as the most preferred model because of the heterogeneity across studies. The computation of the weighted effect size was based on the result from the test of heterogeneity.

Results: Twenty-two studies were finally used in the meta-analysis. The study subjects who received donepezil 5 mg/day, donepezil 10 mg/day, and galantamine 24 mg/day had improved cognition symptoms (ADAS-cog) score of -1.46 (95% CI = -2.24, -0.68, z = 3.67, p < 0.001), -2.31 (95% CI = -3.30, -1.31, z = 5.45, p < 0.001) and -3.04 (95% CI = -4.16, -1.92, z = 5.31, p < 0.001) respectively.

Conclusion: The current meta-analysis suggests significant benefits of cholinesterase inhibitors such as donepezil (5 and 10 mg/day) and galantamine on cognitive symptoms.

Keywords: aging, behavioral symptoms, cholinesterase inhibitors, cognition, dementia, memantine
1 | INTRODUCTION

Dementia is a debilitating disease and a public health problem of concern. It is prevalent in the aging population. Dementia is one of the most common forms of degenerative health problems among the aging population and poses a serious health burden with high socioeconomic costs. The global prevalence of dementia in 2018 was 50 million people. Hence, this was estimated to surge up to 82 million by 2030 and triple to 152 million people by 2050. There is no treatment or effective intervention for Alzheimer’s disease (AD) and it is the most common type of dementia and constitutes 60%–70% of cases. Unfortunately, by the time patients develop dementia, the brain has already suffered serious damage and severely impacts cognition and autonomy. To this end, stringent efforts to develop and implement interventions to manage and mitigate the progress and risks of dementia cannot be over-emphasized. According to Dou et al., the key role medications or interventions play in the management and treatment of dementia, and finding solutions to problems with depression, behavior and cognition cannot be overemphasized.

The treatment of dementia is a major problem. Although numerous clinical trials have been carried out over the years, there is no effective treatment or cure for dementia. It is worthwhile to mention that optimal treatment to avert or delay mild cognitive impairment (MCI), cognitive decline, or dementia is uncertain. Even though pharmacological and non-pharmacological interventions have been introduced, as a remedy for dementia, evidence regarding their safety and efficacy is conflicting and confusing. Pharmacotherapy is often the major intervention implemented to improve symptoms or delay the progression of dementia syndromes. The available agents vary concerning their therapeutic actions and are supported by different levels of evidence for efficacy.

One way to address the menace of AD is to identify and block the candidate enzyme from interrupting the performance of cholinergic neurotransmission in the brain. A family of medicines such as cholinesterase inhibitors was developed to inhibit the activities of the candidate enzyme. Thus, pharmacological interventions such as cholinesterase inhibitors and memantine are the only currently available symptomatic medications for cognition, behavior, and global functioning in patients with dementia. Internationally recognized and accepted cholinesterase inhibitors for treating dementia include donepezil, rivastigmine, and galantamine. They are considered symptomatic therapies and are not believed to be neuroprotective or alter the underlying disease trajectory. Cholinesterase inhibitors offer some relief from the symptoms of AD for some people for a limited period. Cholinesterase inhibitors are identified as very effective in treating AD, not only in the mild-to-moderate stage but also when symptoms become more severe. US Food and Drug Administration (FDA) has approved cholinesterase inhibitors for the symptomatic management and treatment of dementia for AD.

Pharmacological interventions such as donepezil, galantamine, and rivastigmine have been tested in patients with AD and in patients with vascular dementia, dementia with Lewy bodies, dementia associated with Parkinson’s disease, and MCI in the last decade. Even though available information on the effectiveness of these medicines is questionable, the results are often presented in such a way as to create a false perception of efficacy.

Many factors and their interactions might have contributed to the cholinesterase inhibitors tested in primary RCTs not achieving their intended significant therapeutic effects. Factors such as flaws in the design, sample size, inappropriate analysis, and some uncontrolled characteristics of the subjects could grossly affect the quality of the study results. Thus, identifying these extraneous factors in meta-analysis will go a long way to help improve the quality of future clinical trials on a similar topic area. Information on the effectiveness of cholinesterase inhibitors for dementia is conflicting and controversial. This makes it difficult for decision-makers, healthcare providers, patients, and caregivers to decide on the most effective intervention. Thus, this meta-analysis sought to thoroughly conduct a meta-analysis to investigate the effectiveness of pharmacologic interventions to improve cognitive and behavioral symptoms in people with dementia.

2 | METHODS

2.1 | Protocol and registration

The protocol was registered and published with PROSPERO (registration: CRD42020159408) in accordance with the criteria in the preferred reporting items for systematic reviews and meta-analyses (PRISMA). Protocol and registration

2.2 | Types of studies

Studies that included all randomized controlled trials (RCTs), randomizing either individuals or clusters and open-label studies, investigating the effects of pharmacological interventions on cognitive and behavioral symptoms in people with dementia met the inclusion criteria. Studies that have a cognitive symptoms-related outcome measure as a primary outcome were also included. Retrospective, cross-sectional, cohort studies, and quasi-experimental were excluded.

2.3 | Types of participants

Those who were diagnosed of dementia, regardless of type of dementia, setting, age, and the severity of cognitive impairment, were included in the study. Studies where dementia was diagnosed using standard medical or research diagnostic criteria to rule out other conditions and well-documented descriptions of the methods used for assessment were included.
2.4 | Types of interventions

The current study included Pharmacological interventions aiming to improve cognitive and behavioral symptoms in people with dementia. Pharmacological interventions used in this meta-analysis included donepezil (5 and 10 g) and galantamine (24 g). We excluded studies where patients received non-cholinesterase inhibitors and nonpharmacological interventions such as cognitive training, music therapy, aromatherapy, multisensory stimulation, massage, and animal therapy.

2.5 | Control

Comparator interventions included placebo and standard treatment.

2.6 | Outcome measures

Many assessment scales have been developed over the years for use in dementia research and care. However, assessment scales in the areas of behavior and cognition were reviewed in this meta-analysis. AD Assessment Scale-Cognitive (ADAS-cog) and mini-mental state examination (MMSE) were used to measure cognitive symptoms, and neuropsychiatric inventory (NPI) was used to measure behavioral symptoms.

2.7 | Cognition

2.7.1 | ADAS-cog

The ADAS-cog Subscale test is one of the most widely used tools to quantify cognition in medical research studies and clinical trials for new drugs and other interventions. It's more comprehensive than the Mini-Mental State Exam, and it primarily quantifies language, orientation, and memory. The ADAS-Cog comprises of 11 parts and takes nearly 30 min to complete. Most current studies employ the ADAS-Cog to quantify cognitive ability.13

2.7.2 | MMSE

The MMSE is commonly employed to examine cognitive function among the aged population. The medical or clinical researchers with a little training can use the MMSE scale. It takes about 10 min to complete and it measures cognitive functions such as memory, orientation, visual construction attention, X language, and orientation. The score of MMSE scale ranges from 0 to 30 points, and cut-offs of 23/24 have been used to depict significant cognitive impairment.14

2.8 | Behavior

2.8.1 | NPI

The NPI evaluates a wide range of behaviors seen in dementia for both severity and frequency. These include agitation, irritability, delusions, apathy, and depression. The clinician usually administers the NPI scale in 10 min to a career. The NPI scale has good psychometric properties and is commonly employed in drug trials, and is concise enough (especially with patients without a wide range of behavioral issues) to consider for use in clinical practice.15

2.9 | Search strategy, trials selection, and data retrieval

This study used the PRISMA to ensure accuracy and comprehensiveness.31,12 We searched electronic databases including MEDLINE, Embase, Google Scholar, JSTOR, MODEM, and The Cochrane Database. We also searched the Cochrane Controlled Trials Register for studies investigating the effectiveness of donepezil and galantamine for dementia using the MeSH terms such as dementia, vascular dementia, AD, pharmacological interventions, cholinesterase inhibitors, donepezil, and galantamine.

We included Randomized placebo-controlled trials and open-label non-randomized trials. The study excluded case-control and cohort studies, dissertations, editorials, and case reports. Trials with a duration of at least 12 weeks and outcome measures such as cognitive and behavioral symptoms met the inclusion criteria. Patients with dementia who received pharmacological interventions including donepezil (5 and 10 gm), galantamine (24 g), and placebo or comparator RCTs that included quantitative outcome measures of cognitive symptoms (MSME and ADAS-cog) and behavioral symptoms (NPI) were the focus of this study. Two research assistants were tasked to independently assess the relevancy of search results and extract the data into an electronic template designed for this current study. Any disagreements regarding the inclusion of studies were resolved in a consensus meeting. A third reviewer made the definitive decision for study eligibility and data extraction in case of persistent disagreement. We limited the search to articles written and published in English.

2.10 | Searching other resources

We screened reference lists of included trials and the bibliography of recent meta-analysis and systematic reviews and relevant recent guidelines. We obtained from the Authors and experts in the field additional published and unpublished randomized trial reports that could not be identified by the search.
2.11 | Data extraction and analysis

Two trained research assistants independently assessed the relevancy of search results and extracted the data from studies that met the inclusion criteria. Data extracted from each study included detailed characteristics of the trials (settings, outcomes of interest), design features (delivery format, blinding), participant characteristics (diagnoses, age, gender, weight), elements of the experimental and control interventions (frequency, duration, key intervention features). The research assistants obtained information about key variables of interest for investigating the effect moderators such as type of control, sample, country, year of publication, length of follow-up, number of participants in each group. For each outcome of interest, the change in the mean scores from the baseline and standard deviations on relevant measures from all available evaluations were extracted. Intent to treat (ITT) results were recorded, and if not available, then observed case or per-protocol outcomes were extracted.

2.12 | Assessment of risk of bias in included studies

The methodological quality of the relevant studies eligible for inclusion was assessed by two research assistants independently using a modified version of the Scottish Intercollegiate Guidelines Network (SIGN) 50 checklist. SIGN 50 is a validated quality checklist composed of 10 items and encompasses the most important sources of bias and variation observed in randomized clinical trials. All 10 items were considered in this study. Each item was scored as very good (2), good (1), or poor (0). The data collected on these items were entered into Microsoft Excel and transferred to STATA version 15 for data management and further analysis. The amount of agreement between the rating of each research assistant and the consensus rating was explored. Additionally, inter-observer variability by calculating the kappa statistic was examined.

2.13 | Statistical analysis

The data were extracted and entered into the EXCEL template designed for the purpose of this study and further transferred to STATA version 15 and Review Manager (RevMan) version 5.3 for cleaning and analysis. Descriptive statistics were used to summarize the main study characteristics and the risk of bias. A fixed-effect model and random-effect model are the two main types of models that were used to perform a meta-analysis. To decide on which model was the most plausible, a statistical test of heterogeneity across studies in the meta-analysis was examined using $I^2$ statistics (the percentage of variation across studies that is due to between-study heterogeneity rather than chance). $I^2$ of at least 50% were taken as indicators of heterogeneity of outcomes. Thus, random-effects meta-analysis was selected over fixed-effect meta-analysis because of the methodological heterogeneity across studies. Effect sizes for continuous data were calculated as the standardized mean difference (SMD) (Cohen’s $d$) between treatment and control groups. Assessment scales for cognition (ADAS-cog and MMSE) and behavior (NPI) were used to collect continuous data and analysis of the weighted mean difference was conducted. The weighted mean difference reflects the difference in change from baseline to endpoint for active treatments (donepezil and galantamine) and control or comparator group, weighted by the inverse variance. To pool data from studies using different measurement scales for the same outcome, SMD were pooled for continuous outcomes. A $p$-value < 0.05 was considered for statistical significance.

2.14 | Model formulation

2.14.1 | Fixed-effect model

In a fixed-effect model, the usual estimate of a mean effect size consists of weighting every effect estimate, $T_i$, by its inverse variance, $w_i$. The weight assigned to each study is given as $w_i = \frac{1}{V_i}$, where $V_i$ is the within-study variance for study ($i$).

The weighted mean effect is then computed using the equation:

$$ T = \frac{\sum_{i=1}^{k} w_i T_i}{\sum_{i=1}^{k} w_i}, $$

that is, the sum of the products $w_i T_i$ (effect size multiplied by weight) divided by the sum of the weights, where $T_i$ is the observed effect size in study ($i$).

The variance of the combined effect is the reciprocal of the sum of the weights which is given by

$$ V = \frac{1}{\sum_{i=1}^{k} w_i}. $$

The standard error (SE) of the combined effect is the square root of the variance,

$$ SE(T) = \sqrt{V}. $$

2.14.2 | Random-effect modeling

Thus, total variance in random-effect model = within-studies variance + between-studies variance (denoted by $\tau^2$). This is expressed mathematically as $V^*_i = V_i + \tau^2$. An estimator based on the method of moments proposed by DerSimonian and Laird for between-study variance ($\tau^2$) is defined as

$$ \tau^2 = \frac{Q - (k - 1)}{C} = \frac{Q - df}{C}, $$

where $Q$ in the equation is Cochrane’s $Q$ test which represents total variance and $k$ is the number of studies.
If $\tau^2$ is negative then it is set to zero because the variance between studies cannot be negative where $C$ in Equation (4) is a constant and is defined as

$$c = \sum w_i - \frac{\sum w_i^2}{\sum w_i}. \quad (5)$$

Now the weight assigned to each study under random-effect model is given by

$$w_i^* = \frac{1}{v_i^*}. \quad (6)$$

The weighted average therefore is computed as

$$T^* = \frac{\sum_{i=1}^{k} w_i^* \bar{T}_i}{\sum_{i=1}^{k} w_i^*}, \quad (7)$$

that is, the sum of the products $w_i^* \bar{T}_i$ (effect size multiplied by weight) divided by the sum of the weights, where $\bar{T}_i$ is the observed effect size in study (i).

The variance of the combined effect is the reciprocal of the sum of the weights under the random-effect model is defined as

$$v^* = \frac{1}{\sum_{i=1}^{k} w_i^*}. \quad (8)$$

The standard error of the average effect size is the square root of the variance defined as

$$SE(T^*) = \sqrt{v^*}. \quad (9)$$

3 | RESULTS

3.1 | Identification and characteristics of included studies

We initially identified 1270 studies through database search and screening of the reference lists of previous meta-analyses. We selected 151 studies for full-text review shown in the PRISMA diagram (Figure 1). Of the total number of studies initially identified, we removed 500 studies because of duplication. The study excluded 621 titles and abstracts and 129 full-text studies from the meta-analysis for reasons like patients were given non-cholinesterase inhibitors, sample size less than 20, cross-sectional surveys, and case-control were used; qualitative outcomes were measured; and studies were not relevant. We finally included twenty-two studies in the meta-analysis. The included studies were 21 randomized placebo-controlled trials and one open-label extension study, where 11 studies evaluated donepezil (5 and 10 mg/day) and 11 studies investigated the efficacy of galantamine 24 mg/day (Table 1). The duration of follow-up ranged from 12 to 96 weeks. The mean age ranged from 71.9 to 85.7 years.

3.2 | Effectiveness of cholinesterase inhibitors to improve behavior symptoms in people with dementia as measured by NPI

The effect sizes or values less than 0 in the forest plot displayed in Figure 1 shows better results.

In Figure 2, four studies were used in the meta-analysis to investigate the efficacy of donepezil 5 mg/day to improve behavioral symptoms in people with dementia, five studies were used for donepezil 10 mg/day, while six studies were used for galantamine 24 mg/day.

Generally, there is evidence of heterogeneity or effect size is different across the studies for the donepezil 5 mg/day (Cochran $Q = 29.30$, $p < 0.001$, $I^2$ statistic = 90%), donepezil 10 mg/day (Cochran $Q = 45.73$, $p < 0.001$, $I^2$ statistic = 91%) and galantamine 24 mg/day (Cochran $Q = 616.38$, $p < 0.001$, $I^2$ statistic = 99%). The heterogeneity observed across the studies shows conflicting results for the individual studies. There is no evidence to conclude that the weighted or combined difference in the mean change of NPI score for cholinesterase inhibitors are effective in improving behavior symptoms in people with probable dementia. A behavior symptom of 0.18 (95% CI = -2.91, 3.26, z = 0.11, p = 0.91, $\alpha = 0.05$), 0.43 (95% CI = -1.23, 2.09, z = 0.51, p = 0.61, $\alpha = 0.05$) and 0.11 (95% CI = -0.80, 1.02, z = 0.24, p = 0.81, $\alpha = 0.05$) was recorded for patients treated with donepezil 5 mg/day, donepezil 10 mg/day, and galantamine 24 mg/day, respectively.
| Study           | Study type | Intervention          | Number of patients | Mean (SD) Age (years) | Male (%) | Female (%) | Length of follow-up time (weeks) |
|-----------------|------------|-----------------------|--------------------|-----------------------|----------|------------|----------------------------------|
| Ikeda et al^18  | RCT        | Donepezil 5 mg/day    | 45                 | 78.8 (5.1)            | 44.4     | 55.6       | 12                               |
|                 |            | Donepezil 10 mg/day   | 49                 | 77.7 (6.8)            | 42.9     | 57.1       |                                  |
|                 |            | Placebo               | 44                 | 77.2 (6.1)            | 38.6     | 61.4       |                                  |
| Mori^19         | RCT        | Donepezil 5 mg/day    | 32                 | 77.9 (6.8)            | 50.0     | 50.0       | 12                               |
|                 |            | Donepezil 10 mg/day   | 36                 | 78.6 (6.1)            | 11.1     | 88.9       |                                  |
|                 |            | Placebo               | 31                 | 78.6 (4.7)            | 28.1     | 71.9       |                                  |
| Dubois^20       | RCT        | Donepezil 5 mg/day    | 183                | 72.0 (6.8)            | 65.0     | 35.0       | 24                               |
|                 |            | Donepezil 10 mg/day   | 173                | 70.8 (7.5)            | 75.0     | 25.0       |                                  |
|                 |            | Placebo               | 170                | 72.9 (6.5)            | 65.0     | 35.0       |                                  |
| Black^21        | RCT        | Donepezil 5 mg/day    | 198                | 73.7 (0.6)            | 56.1     | 43.9       | 24                               |
|                 |            | Donepezil 10 mg/day   | 206                | 73.9 (0.6)            | 51.9     | 48.1       |                                  |
|                 |            | Placebo               | 199                | 74.2 (0.6)            | 57.8     | 42.2       |                                  |
| Rogers^17       | RCT        | Donepezil 5 mg/day    | 153                | 73.8 (0.67)           | 31.0     | 69.0       | 24                               |
|                 |            | Donepezil 10 mg/day   | 150                | 73.4 (0.65)           | 39.0     | 61.0       |                                  |
|                 |            | Placebo               | 154                | 74.0 (0.65)           | 39.0     | 61.0       |                                  |
| Gustavo^22      | RCT        | Donepezil 5 mg/day    | 399                | 74.2 (0.4)            | 59.4     | 40.6       | 24                               |
|                 |            | Donepezil 10 mg/day   | 398                | 74.8 (0.4)            | 57.2     | 42.8       |                                  |
|                 |            | Placebo               | 383                | 74.3 (0.4)            | 56.1     | 43.9       |                                  |
| Friedhoff       | RCT        | Donepezil 5 mg/day    | 156                | 72.9 (0.6)            | 37.0     | 63.0       | 12                               |
|                 |            | Donepezil 10 mg/day   | 155                | 74.6 (0.6)            | 38.0     | 62.0       |                                  |
|                 |            | Placebo               | 150                | 72.6 (0.6)            | 39.0     | 61.0       |                                  |
| Gustavo^23      | RCT        | Donepezil 5 mgm/day   | 648                | 73.4 (0.4)            | 61.4     | 38.6       | 24                               |
|                 |            | Placebo               | 326                | 72.3 (0.5)            | 54.0     | 46.0       |                                  |
| Ikeda^24        | Open-label | Donepezil 5 mg/day    | 26                 | 78.7 (6.6)            | 50.0     | 50.0       | 52                               |
|                 |            | Donepezil 10 mg/day   | 21                 | 78.2 (6.6)            | 4.3      | 95.7       |                                  |
|                 |            | Placebo               | 28                 | 79.0 (4.6)            | 32.1     | 67.9       |                                  |
| Wilkinson^25    | RCT        | Donepezil 5 mg/day    | 168                | 74.7 (0.6)            | 62.5     | 37.5       | 24                               |
|                 |            | Donepezil 10 mg/day   | 162                | 75.7 (0.6)            | 62.3     | 37.7       |                                  |
|                 |            | Placebo               | 161                | 74.4 (0.6)            | 54.4     | 45.6       |                                  |
| Erkinjuntti^26  | RCT        | Galantamine 24 mg/day | 295                | 74.9 (0.41)           | 52.5     | 47.5       | 48                               |
|                 |            | Placebo               | 164                | 75.6 (0.56)           | 51.8     | 48.2       |                                  |
| Erkinjuntti^27  | RCT        | Galantamine 24 mg/day | 396                | 75.0 (6.84)           | 48.0     | 52.0       | 24                               |
|                 |            | Placebo               | 196                | 75.2 (7.32)           | 46.0     | 54.0       |                                  |
| Chu^28          | open-label | Galantamine           | 32                 | 74.48 (1.61)          | 28.3     | 71.7       | 96                               |
|                 |            | Historical control group | 19            | 78.89 (1.41)         | 26.3     | 73.7       |                                  |
| Tariot^29       | RCT        | Galantamine 24 mg/day | 253                | 77.7 (0.4)            | 33.0     | 67.0       | 17                               |
|                 |            | Placebo               | 255                | 77.1 (0.5)            | 37.8     | 62.2       |                                  |
| Rockwood^30     | RCT        | Galantamine 24 mg/day | 239                | 75.2 (0.45)           | 46.4     | 53.6       | 12                               |
|                 |            | Placebo               | 123                | 74.6 (0.68)           | 43.3     | 56.7       |                                  |
| Study  | Study type | Intervention | Number of patients | Mean (SD) Age (years) | Male (%) | Female (%) | Length of follow-up time (weeks) |
|--------|------------|--------------|--------------------|----------------------|----------|------------|----------------------------------|
| Harandi31 | RCT | Galantamine 24 mg/day | 66 | 72.5 (5.2) | 56.1 | 43.9 | 64 |
| MLC601 | | | 66 | 71.8 (5.7) | 56.1 | 43.9 | |
| Auchus32 | RCT | Galantamine 24 mg/day | 363 | 72.3 (9.0) | 62.0 | 38.0 | 26 |
| | | Placebo | 372 | 72.2 (8.8) | 66.0 | 34.0 | |
| Suh33 | Community-controlled | Galantamine 24 mg/day | 80 | 73.8 (0.8) | 77.5 | 22.5 | 16 |
| | | Placebo | 76 | 76.8 (1.2) | 75.8 | 24.8 | |
| Kurz34 | Open-label | Galantamine 24 mg/day | 150 | 76.2 (7.09) | 53.4 | 46.6 | 96 |
| | | Community control | 76 | 76.8 (7.42) | 60.0 | 40.0 | |
| Wilcock35 | RCT | Galantamine 24 mg/day | 220 | 71.9 (8.3) | 36.8 | 63.2 | 34 |
| | | Placebo | 215 | 72.7 (7.6) | 38.6 | 61.4 | |
| Hager36 | RCT | Galantamine 24 mg/day | 1024 | 73.0 (8.9) | 34.5 | 65.5 | 96 |
| | | Placebo | 1021 | 73.0 (8.7) | 64.1 | 35.9 | |

**FIGURE 2** Forest plot of treatment effect of cholinesterase inhibitors on changes in behavior symptoms as measured by neuropsychiatric inventory.
3.3 Effectiveness of cholinesterase inhibitors to improve cognitive symptoms in people with dementia as measured by ADAS‐cog

Efficacy of donepezil 5 mg/day was reported by seven studies, donepezil 10 mg/day was reported by six studies and 10 studies reported efficacy data for galantamine 24 mg/day (Figure 3). There is evidence of heterogeneity in the combined difference of means for the efficacy of donepezil 5 mg/day (Cochran $Q = 7272.33$, $p < 0.001$, $I^2$ statistic = 100%), donepezil 10 mg/day (Cochran $Q = 10400.38$, $p < 0.001$, $I^2$ statistic = 100%) and galantamine (Cochran $Q = 6184.38$, $p < 0.001$, $I^2$ statistic = 100%). Patients treated with donepezil 5 mg/day, donepezil 10 mg/day, and galantamine 24 mg/day had improved ADAS-cog score of $-1.46$ (95% CI = $-2.24$, $-0.68$, $z = 3.67$, $p < 0.001$, $\alpha = 0.05$), $-2.31$ (95% CI = $-3.30$, $-1.31$, $z = 5.45$, $p < 0.001$, $\alpha = 0.05$) and $-3.04$ (95% CI = $-4.16$, $-1.92$, $z = 5.31$, $p < 0.001$, $\alpha = 0.05$) respectively. The pooled difference in the mean change from baseline Adas-cog total score improved significantly with donepezil 5 mg/day, donepezil 10 mg/day, and galantamine 24 mg/day compared with placebo group.

3.4 Effectiveness of cholinesterase inhibitors to improve cognitive symptoms in people with dementia as measured by MMSE

Nine, eight, and four studies reported efficacy data for donepezil 5 mg/day, donepezil 10 mg/day, and galantamine 24 mg/day, respectively (Figure 4). Extreme heterogeneity was observed for the three cholinesterase inhibitors used (Cochran $Q = 1106.35$, $p < 0.001$, $I^2$ statistic = 99% for donepezil 5 mg/day; Cochran $Q = 92.92$, $p < 0.001$, $I^2$ statistic = 92% for donepezil 10 mg/day; Cochran $Q = 62.09$, $p < 0.001$, $I^2$ statistic = 95% for galantamine). Difference in mean change from baseline on MMSE score favored donepezil 5 mg/day, donepezil 10 mg/day but did not favor galantamine (SMD = 0.93, FIGURE 3 Forest plot of treatment effect of cholinesterase inhibitors on changes in cognitive symptom as measured by Alzheimer's disease assessment scale-cognitive
3.3.1 Donepezil (5 mg/day)

| Study or Subgroup | Weight | IV, Random, 95% CI | Mean Difference |
|-------------------|--------|-------------------|-----------------|
| Black 2003        | 16.0%  | 0.65 [0.61, 0.69] | 0.71            |
| Dubois 2012       | 13.1%  | 1.44 [1.17, 1.71] | 1.16            |
| Friedhoff 1998    | 15.9%  | 1.21 [1.15, 1.27] |                 |
| Gustavo 2005      | 16.1%  | 0.90 [0.88, 0.92] |                 |
| Gustavo 2010      | 16.1%  | 0.47 [0.45, 0.49] |                 |
| Ikeda 2013        | 2.5%   | -1.00 [-2.32, 0.32] |               |
| Ikeda 2015        | 2.4%   | 0.89 [0.53, 1.21] |                 |
| Mori 2012         | 2.1%   | 3.80 [2.34, 5.26] |                 |
| Rogers 1997       | 15.9%  | 0.96 [0.90, 1.02] |                 |
| Subtotal (95% CI) | 100.0% | 0.93 [0.71, 1.16] |                 |

Test for overall effect: Z = 8.12 (P < 0.00001)

Heterogeneity: Tau^2 = 0.08, Chi^2 = 1106.35, df = 8 (P < 0.00001), I^2 = 99%

3.3.2 Donepezil (10 mg/day)

| Study or Subgroup | Weight | IV, Random, 95% CI | Mean Difference |
|-------------------|--------|-------------------|-----------------|
| Black 2003        | 22.4%  | 1.10 [1.06, 1.14] | 1.25            |
| Dubois 2012       | 9.3%   | 1.66 [1.37, 1.95] | 1.13            |
| Friedhoff 1998    | 21.5%  | 1.36 [1.30, 1.42] | 1.36            |
| Gustavo 2005      | 22.8%  | 1.10 [1.07, 1.13] |                 |
| Ikeda 2013        | 0.6%   | -0.10 [-1.51, 1.31] |               |
| Ikeda 2015        | 0.9%   | 1.60 [0.40, 2.80] |                 |
| Mori 2012         | 0.6%   | 2.40 [0.96, 3.84] |                 |
| Rogers 1997       | 21.9%  | 1.26 [1.21, 1.31] |                 |
| Subtotal (95% CI) | 100.0% | 1.25 [1.13, 1.36] |                 |

Test for overall effect: Z = 21.66 (P < 0.00001)

Heterogeneity: Tau^2 = 0.01, Chi^2 = 92.92, df = 7 (P < 0.00001), I^2 = 92%

3.3.3 Galantamine (24 mg/day)

| Study or Subgroup | Weight | IV, Random, 95% CI | Mean Difference |
|-------------------|--------|-------------------|-----------------|
| Chu2007           | 20.7%  | 1.06 [-0.11, 2.23] | 1.21            |
| Erkinjuntti2002   | 28.7%  | -0.70 [-0.82, -0.58] |               |
| Hager2014         | 27.6%  | 0.73 [0.37, 1.09] | 1.21            |
| Harandi2015       | 22.8%  | -0.05 [0.91, 0.91] |                 |
| Subtotal (95% CI) | 100.0% | 0.21 [-0.79, 1.21] |                 |

Test for overall effect: Z = 0.41 (P = 0.68)

Heterogeneity: Tau^2 = 0.91, Chi^2 = 62.09, df = 3 (P < 0.00001), I^2 = 95%

Test for subgroup differences: Chi^2 = 9.69, df = 2 (P = 0.008), I^2 = 79.4%

FIGURE 4 Forest plot of treatment effect of cholinesterase inhibitors on changes in cognitive symptom as measured by mini-mental state examination at endpoint

95% CI = 0.71, 1.16, z = 8.12, p < 0.001, α = 0.05 for donepezil 5 mg/day; SMD = 1.25, 95% CI = 1.13, 1.36, z = 21.66, p < 0.001, α = 0.05 for donepezil 10 mg/day; SMD = 0.21, 95% CI = −0.79, 1.21, z = 0.41, p = 0.68, α = 0.05 for galantamine 24 mg/day).

4 | DISCUSSION

4.1 | Interpretation

This meta-analysis evaluates the effect of cholinesterase inhibitors on cognitive and behavioral and psychological symptoms (BPSD) in people with dementia. Previous studies indicate that pharmacological interventions such as cholinesterase inhibitors are very effective in improving cognitive function and behavioral symptoms in people with dementia, however, there is the need to gather enough evidence for specific pharmacological interventions. In the current study, meta-analysis indicated that cholinesterase inhibitors (donepezil 5 mg/day, donepezil 10 mg/day, and galantamine) are not effective in improving BPSD in people with probable dementia. Thus, the drugs or treatments (donepezil 5 mg/day, donepezil 10 mg/day) administered did not improve the NPI score in comparison to placebo or control group. This current meta-analysis agrees with a recent study conducted by Raina et al.37 to evaluate the effect of donepezil (5 and 10 mg/day) on behavior/mood outcomes, using the NPI, showed no statistically significant changes relative to placebo. A meta-analysis carried out by Dou et al.6 indicated that none of the cognitive enhancers evaluated was likely to improve behavioral symptoms. Thus, this confirms the findings of the current meta-analysis. It is worthwhile that six studies evaluated the effect of galantamine 24 mg/day on BPSD. Four of the six studies demonstrated significant effects of galantamine 24 mg/day on BPSD, while only two studies fail to show an improvement on NPI score relative to placebo. However,
the pooled or combined difference in the mean change of NPI score indicated that galantamine 24 mg/day is not statistically significantly effective in improving behavior symptoms in people with mild and probable dementia (MD = 0.11, 95% CI = -0.80, 1.02, z = 0.24, p = 0.81, a = 0.05).

The current meta-analysis also suggests a significant benefit of cholinesterase inhibitors such as donepezil (5 and 10 mg/day) and galantamine relative to placebo on cognitive symptoms. Thus, the findings of the current study are in concordance with a previous meta-analysis where 10 trials in 3239 people with mild to moderate dementia were reviewed to evaluate the effect of donepezil (5 and 10 mg/day) relative to placebo demonstrated consistent evidence of benefit in the domains of cognitive function on ADAS-cog.38 Another researcher reviewed two large-scales randomized trials for donepezil (10 mg/day) intervention where 1219 patients with probable or possible vascular cognitive impairment were enrolled and followed up for 24 weeks.39 Similar to the findings of the current study, the meta-analysis they performed showed benefits associated with donepezil (10 mg/day) compared to placebo on cognitive function.

4.2 | Strengths of the study

The use of meta-analysis has improved the power of the effects of interest because of the increase in the sample size when a number of studies were combined. The use of meta-analysis produces precise effects estimate and it is beneficial relative to systematic reviews. The findings from the meta-analysis are more reliable than results of primary studies.

4.3 | Limitations of the study

Even though we identified all relevant studies, there is an increased probability of overestimating the actual effect size because the meta-analysis included only published studies. We did not apply Eagger's linear regression test to adjust for the observed bias.

5 | CONCLUSION

The current meta-analysis suggests a significant benefit of cholinesterase inhibitors such as donepezil (5 and 10 mg/day) and galantamine on cognitive symptoms. However, the combined difference in the mean change of NPI score indicated that donepezil (5 and 10 mg/day) and galantamine are not effective in improving BPSD in people with probable dementia. Based on the results of the current meta-analysis, the food and drugs authority of various countries should consider the approval of donepezil (5 and 10 mg/day) and galantamine for the treatment of cognition symptoms of people with dementia.

AUTHOR CONTRIBUTIONS

Wisdom K. Takramah: Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; validation; visualization; writing – original draft; writing – review and editing. Livingstone Asem: Data curation; investigation; methodology; project administration; resources; writing – review and editing.

ACKNOWLEDGMENT

Special appreciation goes to Prof. Adanu and Prof. Yawson for their insights.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

TRANSPARENCY STATEMENT

The lead author Wisdom Kwami Takramah affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

ORCID

Wisdom K. Takramah http://orcid.org/0000-0003-1124-7300

REFERENCES

1. Olanrewaju O, Clare L, Barnes L, Brayne C. A multimodal approach to dementia prevention: a report from the Cambridge Institute of Public Health. Alzheimer’s Dement Transl Res Clin Interv. 2015;1(3): 151-156.
2. Patterson CE, Passmore AP, Crawford VLS. A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer’s disease. Int J Clin Pract. 2004;58(2):144-148.
3. World Health Organization. Global Action Plan on the Public Health Response to Dementia 2017–2025. World Health Organization; 2017:52. http://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/
4. Ritchie CW, Terrera GM, Quinn TJ. Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. Alzheimer’s Res Ther. 2015;7:1-11.
5. Pereira T, Lemos L, Cardoso S, et al. Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows. BMC Med Inform Decis Mak. 2017;17(1):1-15.
6. Dou K, Tan M, Tan C, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta- analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;9:1-10.
7. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;2018(6):3-6.
8. Mushker K, Augustyn M. Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc. 2018;10:1-126.
9. Juan YC, Yue Z, Yuan WJ. Efficacy of cholinesterase inhibitors in vascular dementia: an updated. *Eur. Neurol.* 2016;75(3-4):132-141.
10. Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with Lewy bodies. *Drugs and Aging.* 2019;36(4):309-319. doi:10.1007/s40266-018-00636-7
11. Blondell SJ, Hammersley-mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia: a systematic review and meta-analysis of longitudinal studies. *BMC Public Health.* 2014;14:1-12.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009;6:e1000100.
13. Heerema E. Use and scoring of the ADAS-Cog test. *Brain Nerv Syst.* 2018;1-14. https://www.verywellhealth.com/alzheimers-disease-assessment-scale-98625
14. Tantillo BA. *Machine Learning IDs Markers to Help Predict Alzheimer’s* [Internet]. 2019:1-4. https://www.bnl.gov/newsroom/news.php?a=212916
15. Sheehan B. Assessment scales in dementia. *Ther Adv Neurol Disord.* 2012;5:349-358.
16. Bai A, Shukla VK, Bak G, Wells G. Quality Assessment Tools Project Report [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2012. https://www.cadth.ca/sites/default/files/pdf/QAT_final.pdf
17. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. *Arch Intern Med.* 1998;158(9):1021-1031.
18. Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. *Alzheimer’s Res Ther.* 2015;7(1):1-10. doi:10.1186/s13195-014-0083-0
19. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. *Ann Neurol.* 2012;72(1):41-52.
20. Dubois B, Tolosa E, Katzschnegler R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. *Mov Disord.* 2012;27(10):1230-1238.
21. Stephan B, Brayne C. Prevalence and projections of dementia. *Princ Perspect.* 2003;2003:9-34.
22. Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. *Dement Geriatr Cogn Disord.* 2005;20(6):338-344.
23. Román GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. *Stroke.* 2010;41(6):1213-1221.
24. Ikeda M, Mori E, Kosaka K, et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. *Dement Geriatr Cogn Disord.* 2013;36(3-4):229-241.
25. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. *Neurology.* 2003;61(4):479-486.
26. Erkinjuntti T. Erratum: an open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. *Clin Ther.* 2003;25(8):2336.
27. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CRV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. *Lancet.* 2002;359(9314):1283-1290.
28. Chu LW, Yik PY, Mok W, Chung CP. A 2-year open-label study of galantamine therapy in Chinese Alzheimer’s disease patients in Hong Kong. *Int J Clin Pract.* 2007;61(3):403-410.
29. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. *Neurology.* 2000;54(12):2269-2276.
30. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer’s disease: a rando-
mised, controlled trial. *J Neurol Neurosurg Psychiatry.* 2001;71(5):589-595.
31. Hager K, Baseman AS, Nye JS, et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study. *Alzheimer’s Res Ther.* 2016;8(1):1-10. doi:10.1186/s13195-016-0214-x
32. Auchus AP, Brashar HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. *Neurology.* 2007;69(5):448-458.
33. Suh GH, Yeon Jung H, Uk Lee C, et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population. *Clin Ther.* 2004;26(10):1608-1618.
34. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Venkata Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer’s disease with cerebrovascular disease. *Eur J Neurol.* 2003;10(6):633-640.
35. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicontremped randomised controlled trial. *Br Med J.* 2000;321(7274):1445-1449.
36. Hager K, Baseman AS, Nye JS, et al. Effects of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study. *Alzheimer’s Res Ther.* 2016;8(1):1-10. doi:10.1186/s13195-016-0214-x
37. Santaguida PS, Raina P, Booker L, et al. Pharmacological treatment of dementia: summary. *AHRQ Evid Rep Summ.* 2004;(April):1-19.
38. Maggini M, Vanacore N, Raschetti R. Cholinesterase Inhibitors: drugs looking for a disease? *PLoS Med.* [Internet]. 2006;3(4).
39. Malouf R, Birks J. Donepezil for cognitive impairment (review). *Cochrane Database Syst Rev.* 2010;1:CD004395. doi:10.1002/14651858.CD004395.pub2

How to cite this article: Takramah WK, Asem L. The efficacy of pharmacological interventions to improve cognitive and behavior symptoms in people with dementia: a systematic review and meta-analysis. *Health Sci Rep.* 2022;5:e913. doi:10.1002/hsr.2913